Total Payments
$5,763
2024 Payments
$1,578
Companies
47
Transactions
257
Medicare Patients
5,859
Medicare Billing
$599,193
Payment Breakdown by Category
Food & Beverage$3,463 (60.1%)
Other$1,665 (28.9%)
Education$634.50 (11.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,463 | 209 | 60.1% |
| Long term medical supply or device loan | $1,665 | 19 | 28.9% |
| Education | $634.50 | 29 | 11.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,199 | 51 | $0 (2024) |
| PFIZER INC. | $479.55 | 33 | $0 (2024) |
| Genentech USA, Inc. | $360.43 | 22 | $0 (2023) |
| Astellas Pharma US Inc | $225.85 | 9 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $196.54 | 7 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $175.08 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $170.19 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $148.71 | 3 | $0 (2022) |
| Janssen Biotech, Inc. | $144.74 | 11 | $0 (2023) |
| ARRAY BIOPHARMA INC | $140.19 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,578 | 43 | Novartis Pharmaceuticals Corporation ($1,088) |
| 2023 | $1,095 | 51 | Novartis Pharmaceuticals Corporation ($389.70) |
| 2022 | $1,258 | 55 | Novartis Pharmaceuticals Corporation ($546.09) |
| 2021 | $112.27 | 7 | Novartis Pharmaceuticals Corporation ($30.46) |
| 2020 | $229.99 | 9 | Astellas Pharma US Inc ($118.57) |
| 2019 | $390.60 | 26 | Genentech USA, Inc. ($54.57) |
| 2018 | $638.82 | 36 | Janssen Products, LP ($99.95) |
| 2017 | $460.07 | 30 | Pharmacyclics LLC, An AbbVie Company ($104.26) |
All Payment Transactions
257 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: ONCOLOGY | ||||||
| 07/01/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Immunology | ||||||
| 06/14/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Oncology | ||||||
| 06/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 05/29/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.61 | General |
| 05/17/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 05/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.42 | General |
| Category: Oncology | ||||||
| 04/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 04/15/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,485 | 4,395 | $356,390 | $157,372 |
| 2022 | 11 | 1,495 | 4,492 | $361,853 | $151,139 |
| 2021 | 11 | 1,538 | 4,078 | $360,490 | $165,560 |
| 2020 | 12 | 1,341 | 3,615 | $297,605 | $125,122 |
Total Patients
5,859
Total Services
16,580
Medicare Billing
$599,193
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 345 | 617 | $113,528 | $52,209 | 46.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 151 | 380 | $97,588 | $49,593 | 50.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 386 | 1,593 | $20,692 | $13,366 | 64.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 377 | 1,499 | $55,463 | $11,395 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 68 | 68 | $22,508 | $10,440 | 46.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 44 | $14,432 | $5,791 | 40.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 60 | $7,020 | $3,660 | 52.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 40 | $6,760 | $3,619 | 53.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 22 | 23 | $9,154 | $2,950 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 25 | $3,225 | $1,568 | 48.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $3,380 | $1,518 | 44.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 33 | $2,640 | $1,263 | 47.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 168 | 440 | $113,080 | $56,623 | 50.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 359 | 626 | $115,159 | $52,681 | 45.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 391 | 1,565 | $57,905 | $12,003 | 20.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 72 | 72 | $23,832 | $11,543 | 48.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 396 | 1,630 | $19,560 | $4,830 | 24.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 27 | 28 | $9,184 | $4,208 | 45.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 47 | $7,943 | $3,657 | 46.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 21 | 21 | $8,358 | $2,670 | 32.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 30 | $3,510 | $1,592 | 45.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $2,860 | $1,220 | 42.7% |
| 82565 | Blood creatinine level | Office | 2022 | 12 | 22 | $462.00 | $111.19 | 24.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 187 | 476 | $114,352 | $63,131 | 55.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 334 | 561 | $97,866 | $49,764 | 50.8% |
About Dr. Jess Armor, M.D
Dr. Jess Armor, M.D is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922059666.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jess Armor, M.D has received a total of $5,763 in payments from pharmaceutical and medical device companies, with $1,578 received in 2024. These payments were reported across 257 transactions from 47 companies. The most common payment nature is "Food and Beverage" ($3,463).
As a Medicare-enrolled provider, Armor has provided services to 5,859 Medicare beneficiaries, totaling 16,580 services with total Medicare billing of $599,193. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 05/15/2006
- Last Updated 04/24/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1922059666
Products in Payments
- KISQALI (Drug) $1,420
- XTANDI (Drug) $208.37
- Imbruvica (Drug) $196.54
- IBRANCE (Drug) $172.44
- KEYTRUDA (Biological) $170.19
- OPDIVO (Biological) $160.72
- PROMACTA (Drug) $151.26
- TECENTRIQ (Biological) $141.63
- LYNPARZA (Drug) $133.71
- MEKINIST (Drug) $117.73
- VENCLEXTA (Biological) $106.24
- Cabometyx (Drug) $103.95
- ZYTIGA (Drug) $99.95
- REBLOZYL (Biological) $95.56
- DARZALEX (Biological) $84.83
- VENCLEXTA (Drug) $80.35
- BRAFTOVI (Drug) $79.68
- PLUVICTO (Drug) $75.04
- Onivyde (Drug) $64.92
- BRUKINSA (Drug) $63.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791